The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
Adriaan E Basson; Matshediso Ntsala; Neil Martinson; Emily Tlale; Gary E Corrigan; Xingwu Shao; Glenda Gray; James McIntyre; Adrian Puren; Lynn Morris (Profiled Author: Neil Martinson)
AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa.
Journal of acquired immune deficiency syndromes (1999) 2008;49(5):538-43.
OBJECTIVES: Single-dose nevirapine (sdNVP) used to prevent mother-to-child transmission of HIV-1 results in the selection of genotypic drug resistance mutations. To assess the levels of phenotypic resistance conferred by these mutations, we examined the ability of sample-derived HIV-1 reverse transcriptase to function in the presence of nevirapine (NVP). METHODS: Plasma samples from HIV-1 pregnant women before and after exposure to sdNVP were used to extract viral reverse transcriptase for the Cavidi ExaVir Drug susceptibility assay. The fold increases in phenotypic resistance for each sample were compared with the genotypic profiles determined by population-based sequencing. RESULTS: None of the women sampled before sdNVP exposure had phenotypic resistance (median fold increase 0.7). Seven weeks after sdNVP, there was a 16-fold increase in phenotypic resistance among women who had NVP resistance mutations compared with only a 1.9-fold increase among NVP-exposed women with wild-type virus. Phenotypic resistance decayed with time coincident with the fading of genotypic mutations, and by 18 months, all samples were phenotypically susceptible. CONCLUSIONS: Exposure of pregnant women to sdNVP was associated with the transient appearance of viral populations that displayed phenotypic resistance to NVP. Overall, there was good concordance between phenotypic resistance to NVP, as measured with this enzymatic assay, and the presence of NVP genotypic mutations.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Tamara Flys; Dwight V Nissley; Cassidy W Claasen; Dana Jones; Chanjuan Shi; Laura A Guay; Philippa Musoke; Francis Mmiro; Jeffrey N Strathern; J Brooks Jackson; et al.
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.The Journal of infectious diseases 2005;192(1):24-9.
S H Eshleman; L A Guay; A Mwatha; S P Cunningham; E R Brown; P Musoke; F Mmiro; J B JacksonAIDS research and human retroviruses 2004;20(6):595-9.
Deborah Persaud; Abubaker Bedri; Carrie Ziemniak; Anitha Moorthy; Berhanu Gudetta; Aida Abashawl; Yohannes Mengistu; Saad B Omer; Abdulhamid Isehak; Solomon Kumbi; et al.AIDS research and human retroviruses 2011;27(8):823-9.
Appears in this Publication
Author of this Publication